Details of Disease

General Information of Disease (ID: DIS2TXP8)

Disease Name	Thrombosis
Synonyms	thrombus; thrombotic disorder; thrombosis; clot, blood; blood clot; blood Clots; Thromboses; Clots, blood
Disease Class	DB61-GB90: Thrombosis
Definition	The formation of a blood clot in the lumen of a vessel or heart chamber; causes include coagulation disorders and vascular endothelial injury.
Disease Hierarchy	DISVS67S: Vascular disease DIS2TXP8: Thrombosis
ICD Code	ICD-11 ICD-11: DB61-GB90
Disease Identifiers	MONDO ID MONDO_0000831 MESH ID D013927 UMLS CUI C0040053 MedGen ID 21160 SNOMED CT ID 118927008

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 13 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Acenocoumarol	DMH75KV	Approved	Small molecular drug	[1]
Apixaban	DM89JLN	Approved	Small molecular drug	[2]
Ardeparin	DMYRX8B	Approved	Small molecular drug	[3]
Argatroban	DMFI46A	Approved	Small molecular drug	[4]
Biciromab	DMAW8W9	Approved	Monoclonal antibody	[5]
Brilinta	DMBR01X	Approved	Small molecular drug	[6]
Cangrelor	DM8JRH0	Approved	Small molecular drug	[7]
Clopidogrel	DMOL54H	Approved	Small molecular drug	[8]
Dextran	DMBFLML	Approved	Small molecular drug	[5]
Dicumarol	DMFQCB1	Approved	Small molecular drug	[9]
Lprivask	DM17TE1	Approved	NA	[10]
Phenprocoumon	DMDO279	Approved	Small molecular drug	[11]
Warfarin	DMJYCVW	Approved	Small molecular drug	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 13 Drug(s)

This Disease is Treated as An Indication in 47 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Amediplase	DM4FPM3	Phase 3	Small molecular drug	[13]
AS-013	DMD7XWS	Phase 3	Small molecular drug	[14]
Heparin low molecular weight	DMGFULM	Phase 3	NA	[15]
SSR-126517E	DMT71EX	Phase 3	NA	[16]
Tecarfarin	DMTCR2O	Phase 3	Small molecular drug	[12]
Unfractionated heparin	DMCWM03	Phase 3	NA	[17]
CONTIGOSIDE B	DMX9V8K	Phase 2/3	Small molecular drug	[12]
ASC-J9	DMDQS4W	Phase 2	Small molecular drug	[18]
BAY1213790	DMZPB6G	Phase 2	NA	[12]
BAY2306001	DMRB103	Phase 2	NA	[12]
BMS-986141	DMTKDIP	Phase 2	Small molecular drug	[19]
BMS-986177	DM4QHZS	Phase 2	Small molecular drug	[20]
EP-217609	DMPC4EK	Phase 2	NA	[21]
GW-813893	DMH0C8J	Phase 2	NA	[22]
Ifetroban sodium	DMZP84Y	Phase 2	Small molecular drug	[23]
IONIS-416858	DM5F0QY	Phase 2	Antisense oligonucleotide	[24]
LY-517717	DM8OG0J	Phase 2	Small molecular drug	[25]
MK-2060	DM79A32	Phase 2	Monoclonal antibody	[26]
NU-172	DMORNVB	Phase 2	NA	[27]
Recombinant RGD-hirudin	DMV0A28	Phase 2	NA	[28]
Saruplase	DM1M0PR	Phase 2	NA	[29]
ZK-001	DMDJSOH	Phase 1/2	NA	[30]
192C86	DMQ8NTZ	Phase 1	Small molecular drug	[31]
AjvW2	DM6PN4H	Phase 1	Antibody	[32]
ARL-67085	DMY5IM2	Phase 1	Small molecular drug	[33]
AZD-8165	DM8DMI0	Phase 1	Small molecular drug	[34]
BI-11634	DMKQHE5	Phase 1	NA	[35]
BIBT986	DMP70FI	Phase 1	Small molecular drug	[36]
BMS-986120	DMYLFQR	Phase 1	Small molecular drug	[37]
DA-697b	DMBRN2G	Phase 1	NA	[38]
DIAPLASININ	DM6OJI1	Phase 1	Small molecular drug	[39]
EP-42675	DMKR3GD	Phase 1	NA	[40]
EP-7041	DMV0MHI	Phase 1	NA	[12]
G-619	DM3H6YC	Phase 1	Small molecular drug	[41]
GCC-4401	DMHMZC7	Phase 1	NA	[42]
IChorcumab	DMR065Z	Phase 1	NA	[12]
ION547	DMVNKNJ	Phase 1	Gene therapy	[43]
MER-102	DME18UM	Phase 1	NA	[44]
Octaplas LG	DM1W3Z7	Phase 1	NA	[45]
PSI-697	DM75FWO	Phase 1	Small molecular drug	[46]
RGD-891	DMVJMF1	Phase 1	NA	[47]
RWJ-671818	DMJVCS1	Phase 1	Small molecular drug	[48]
SDZ-GPI-562	DMU9ZGN	Phase 1	NA	[49]
Solulin	DMB3WJF	Phase 1	NA	[50]
SSR-128428	DMOJA7N	Phase 1	NA	[51]
TS23	DMU5UYF	Phase 1	NA	[12]
UK-396082	DMFYKDX	Phase 1	Small molecular drug	[52]
------------------------------------------------------------------------------------


⏷ Show the Full List of 47 Drug(s)

This Disease is Treated as An Indication in 79 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Domitroban	DM3OUWC	Discontinued in Preregistration	Small molecular drug	[53]
Satigrel	DM4LSJ2	Discontinued in Preregistration	Small molecular drug	[54]
Fibrimage	DMLMYHK	Discontinued in Phase 3	NA	[55]
Idraparinux	DM3SKAC	Discontinued in Phase 3	Small molecular drug	[56]
RB-006	DMAINU1	Discontinued in Phase 3	NA	[57]
Taprostene	DMA4WY5	Discontinued in Phase 3	Small molecular drug	[58]
Terutroban sodium	DMYF1DN	Discontinued in Phase 3	Small molecular drug	[59]
Octopamine	DMLQVTJ	Discontinued in Phase 2a	Small molecular drug	[60]
99mTc-NC-100668	DMJVLZ2	Discontinued in Phase 2	NA	[61]
AZD-9684	DMHA5ME	Discontinued in Phase 2	Small molecular drug	[62]
AZD0837	DMA9Q2V	Discontinued in Phase 2	Small molecular drug	[63]
Bervastatin	DMEK6J0	Discontinued in Phase 2	Small molecular drug	[64]
E-3040	DM35KZG	Discontinued in Phase 2	Small molecular drug	[65]
Egaptivon pegol	DMR9565	Discontinued in Phase 2	NA	[66]
ELAROFIBAN	DM7TM91	Discontinued in Phase 2	Small molecular drug	[67]
EP-5001	DMXB43C	Discontinued in Phase 2	NA	[21]
Flovagatran	DMN1C2E	Discontinued in Phase 2	Small molecular drug	[68]
ICI-192605	DMY8X6Q	Discontinued in Phase 2	Small molecular drug	[69]
Linotroban	DM32JL5	Discontinued in Phase 2	Small molecular drug	[70]
MK-852	DMBJLZG	Discontinued in Phase 2	Small molecular drug	[71]
PD-348292	DMMYNKH	Discontinued in Phase 2	Small molecular drug	[72]
SPD 535	DM1O2TX	Discontinued in Phase 2	NA	[73]
SQ-30741	DMTC4VY	Discontinued in Phase 2	Small molecular drug	[74]
SR-121787	DMCEQKG	Discontinued in Phase 2	Small molecular drug	[75]
TAK-442	DMG4RFO	Discontinued in Phase 2	Small molecular drug	[76]
Z-335	DM2438J	Discontinued in Phase 2	Small molecular drug	[77]
AVE-3247	DMMPBZF	Discontinued in Phase 1	NA	[78]
CJC-1004	DM3Q8UW	Discontinued in Phase 1	NA	[79]
DMP-728	DMCK7LM	Discontinued in Phase 1	Small molecular drug	[80]
DPC 423	DMR6INY	Discontinued in Phase 1	Small molecular drug	[81]
EMD-503982	DMQH8L2	Discontinued in Phase 1	NA	[82]
FR-158999	DM5FW8Y	Discontinued in Phase 1	Small molecular drug	[83]
JTV-803	DMXUH6W	Discontinued in Phase 1	Small molecular drug	[84]
KT2-962	DMBH5G3	Discontinued in Phase 1	Small molecular drug	[85]
KW-3635	DMG068H	Discontinued in Phase 1	Small molecular drug	[86]
L-734217	DMSB0J8	Discontinued in Phase 1	Small molecular drug	[87]
ME-3277	DMUMSFR	Discontinued in Phase 1	NA	[88]
MPC-0920	DMMVG34	Discontinued in Phase 1	NA	[89]
SC-52012	DMFC19E	Discontinued in Phase 1	Small molecular drug	[90]
TAK-029	DMN02XD	Discontinued in Phase 1	NA	[91]
TIPLASININ	DMM6NKA	Discontinued in Phase 1	Small molecular drug	[92]
TP-9201	DMCV2KQ	Discontinued in Phase 1	Small molecular drug	[93]
YM-75466	DMDJ2O5	Discontinued in Phase 1	NA	[94]
ZD-4927	DMQDNU1	Discontinued in Phase 1	NA	[95]
APT-222	DMWXYZT	Terminated	NA	[98]
AZD-0303	DMS2IWB	Terminated	NA	[99]
AZD-1283	DM9AWS7	Terminated	Small molecular drug	[100]
AZD6482	DMVP4E5	Terminated	Small molecular drug	[101]
BCH-2763	DM3TP8X	Terminated	Small molecular drug	[102]
BIBU-251	DMMNI5K	Terminated	NA	[103]
BX-044	DM0P8CE	Terminated	NA	[104]
Draculin	DMX4KIT	Terminated	NA	[105]
DuP 714	DMZOCHT	Terminated	Small molecular drug	[106]
FCE-24265	DM0GE8K	Terminated	Small molecular drug	[107]
FR-171113	DMIQB9E	Terminated	Small molecular drug	[108]
Fradafiban	DMN4E5H	Terminated	Small molecular drug	[109]
GR-144053	DMN8TH1	Terminated	Small molecular drug	[110]
GR-233548	DMHM0EU	Terminated	NA	[111]
GS-522	DMT6S9B	Terminated	NA	[112]
Hementin	DM5HMZW	Terminated	NA	[113]
Hirufaxin	DM784QJ	Terminated	NA	[114]
Itazigrel	DMJ6VF4	Terminated	Small molecular drug	[115]
L-373890	DMOKZ2V	Terminated	NA	[116]
L-374,087	DMK2QW0	Terminated	NA	[117]
L-703014	DM47MKE	Terminated	Small molecular drug	[118]
MDL-28133A	DM6X4IT	Terminated	Small molecular drug	[119]
MOL-2591	DMM37RU	Terminated	NA	[120]
NPI-1999	DMH1YL8	Terminated	NA	[121]
Org-34092	DM3VWZF	Terminated	NA	[122]
SB-208651	DMJD15H	Terminated	Small molecular drug	[123]
SKF-106760	DM7QPYK	Terminated	Small molecular drug	[124]
SQ-33961	DMZBQ4I	Terminated	Small molecular drug	[125]
SR-80027A	DM6ASLF	Terminated	NA	[126]
Tridegin	DMUHBSI	Terminated	NA	[127]
UP-116-77	DMEIR7F	Terminated	Small molecular drug	[128]
UR-12460	DMV8GUE	Terminated	NA	[129]
XR-1853	DMFHR2O	Terminated	Small molecular drug	[130]
XR-5082	DMEVSZO	Terminated	Small molecular drug	[131]
ZK-118182	DMJZH7N	Terminated	Small molecular drug	[132]
------------------------------------------------------------------------------------


⏷ Show the Full List of 79 Drug(s)

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CS-3030	DMK230A	Preclinical	NA	[96]
TGX-6B4	DM1KTOC	Preclinical	Antibody	[97]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 19 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
99mTc-biciromab	DMRJOL7	Investigative	Monoclonal antibody	[133]
ABX-201	DM9YV81	Investigative	Small molecular drug	[133]
CDRI-S002-333	DMKH4HR	Investigative	NA	[133]
CDRI-S007-867	DMPKOTN	Investigative	NA	[133]
DT-831j	DM3TMUK	Investigative	NA	[134]
FXI-AS1	DMAZ1NW	Investigative	Antisense drug	[135]
GC-2107	DM46HAS	Investigative	NA	[134]
IMD-4852	DMVKTY0	Investigative	NA	[133]
MN-462	DM1XY5F	Investigative	NA	[136]
NLP-91	DM9MRO3	Investigative	NA	[133]
NP-313	DMOMVC2	Investigative	NA	[133]
ONO-8809	DM5BMA9	Investigative	Small molecular drug	[137]
PRT-060318	DMQPEA7	Investigative	NA	[138]
REG-3	DMIM5CW	Investigative	NA	[133]
RGD-039	DM0O9VG	Investigative	NA	[139]
SCH-205831	DM584T6	Investigative	Small molecular drug	[140]
SN429	DMP4IJ6	Investigative	Small molecular drug	[141]
TA-102	DMTC4VK	Investigative	NA	[133]
TA-264	DM71XJ6	Investigative	NA	[133]
------------------------------------------------------------------------------------


⏷ Show the Full List of 19 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 61 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
F11	TTDM4ZU	Limited	Biomarker	[142]
F13A1	TTXI2RA	Limited	Genetic Variation	[143]
F3	TT38MDJ	Limited	Biomarker	[144]
FGG	TTR31L7	Limited	Biomarker	[145]
GP6	TTTJUVZ	Limited	Biomarker	[146]
PIK3CB	TT9H4P3	Limited	Biomarker	[147]
PROC	TTZUXYS	Limited	Biomarker	[148]
SCUBE2	TTWREQP	Limited	Altered Expression	[149]
SERPINE1	TTTO43N	Limited	Biomarker	[150]
TBXA2R	TT2O84V	Limited	Biomarker	[151]
TUBB1	TT63KYR	Limited	Genetic Variation	[152]
VKORC1	TTEUC8H	Limited	Biomarker	[153]
VWF	TT3SZBT	Limited	Biomarker	[150]
APOH	TT2OUI9	moderate	Biomarker	[154]
ITGA2	TTSJ542	moderate	Biomarker	[155]
ITGB3	TTJA1ZO	moderate	Biomarker	[156]
ACE2	TTUI5H7	Strong	Therapeutic	[157]
ADAMTS13	TTUREBK	Strong	Biomarker	[158]
AGT	TT5C0UB	Strong	Therapeutic	[159]
BDKRB2	TTGY8IW	Strong	Biomarker	[160]
C5AR1	TTHXFA1	Strong	Biomarker	[161]
CD2	TTJDUNO	Strong	Biomarker	[162]
CD40LG	TTIJP3Q	Strong	Therapeutic	[163]
CPB2	TTP18AY	Strong	Genetic Variation	[164]
CRP	TTWRN6M	Strong	Biomarker	[165]
CYP2C19	TTZ58XG	Strong	Biomarker	[166]
CYP3A5	TTHS0OK	Strong	Biomarker	[167]
EPO	TTQG4NR	Strong	Biomarker	[168]
F10	TTCIHJA	Strong	Biomarker	[169]
F2	TT6L509	Strong	Biomarker	[170]
F5	TT1O264	Strong	Altered Expression	[171]
F8	TT1290U	Strong	Biomarker	[172]
F9	TTFEZ5Q	Strong	Biomarker	[169]
FCGR2A	TTXT21W	Strong	Altered Expression	[173]
FLT3	TTGJCWZ	Strong	Biomarker	[162]
FUT4	TTNV1KZ	Strong	Biomarker	[162]
GAS6	TT69QD2	Strong	Biomarker	[174]
GP1BA	TTVB0Q9	Strong	Biomarker	[175]
HGF	TT4V2JM	Strong	Biomarker	[176]
HMOX1	TTI6V2A	Strong	Therapeutic	[177]
KLF4	TTTI53X	Strong	Therapeutic	[144]
KLKB1	TTN0PCX	Strong	Biomarker	[144]
MAS1	TTOISYB	Strong	Therapeutic	[144]
MERTK	TTO7LKR	Strong	Biomarker	[178]
MPL	TTIHYA4	Strong	Genetic Variation	[179]
P2RX1	TTJW7B3	Strong	Biomarker	[180]
P2RY1	TTA93TL	Strong	Biomarker	[175]
P2RY12	TTZ1DT0	Strong	Biomarker	[181]
PDE3A	TT06AWU	Strong	Biomarker	[182]
PF4	TTSG7Q5	Strong	Biomarker	[183]
PLAT	TTXAGYU	Strong	Therapeutic	[150]
PLAU	TTGY7WI	Strong	Biomarker	[184]
PTGER3	TTPNGDE	Strong	Biomarker	[185]
SELP	TTE5VG0	Strong	Biomarker	[186]
SERPINC1	TT4QPUL	Strong	Therapeutic	[187]
SIRT1	TTUF2HO	Strong	Therapeutic	[144]
TBXAS1	TTKNWZ4	Strong	Biomarker	[188]
TFPI	TT068JH	Strong	Altered Expression	[189]
THBD	TTAPV67	Strong	Biomarker	[190]
TYRO3	TTIEMFN	Strong	Biomarker	[191]
VHL	TTEMWSD	Strong	Biomarker	[192]
------------------------------------------------------------------------------------


⏷ Show the Full List of 61 DTT(s)

This Disease Is Related to 10 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CANT1	OT1TPWQR	Limited	Biomarker	[193]
CD177	OTS79FNF	Limited	Altered Expression	[194]
FGB	OT6RKLI9	Limited	Biomarker	[195]
ICAM4	OT1BI27E	Limited	Biomarker	[196]
SCUBE1	OT4JY1UY	Limited	Altered Expression	[149]
FGA	OTMIHY80	Strong	Biomarker	[197]
GUCY1A1	OTPTCBUN	Strong	Biomarker	[198]
PODXL	OTPNQXF3	Strong	Biomarker	[199]
PROCR	OTRHED17	Strong	Genetic Variation	[200]
PROS1	OTXQWNOI	Strong	Biomarker	[201]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 DOT(s)

References

1	Drug information of Acenocoumarol, 2008. eduDrugs.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6390).
3	Clinical pipeline report, company report or official report of Emisphere Technologies Inc.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6385).
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1765).
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1776).
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7150).
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6808).
10	Clinical pipeline report, company report or official report of Canyon pharmaceuticals.
11	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6839).
12	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13	Amediplase: CGP 42935, K2tu-PA, MEN 9036. BioDrugs. 2002;16(5):378-9.
14	Effect of lipo-pro-prostaglandin E1, AS-013 on rat inner ear microcirculatory thrombosis. Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):203-7.
15	Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc. 2006 Jun;81(6):758-67.
16	ClinicalTrials.gov (NCT00345618) Clinical Study Assessing SSR126517E Injections Once-weekly in Pulmonary Embolism Therapeutic Approach. U.S. National Institutes of Health.
17	Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. Am Heart J. 2002 Feb;143(2):229-34.
18	ClinicalTrials.gov (NCT03612856) Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis. U.S. National Institutes of Health.
19	ClinicalTrials.gov (NCT02671461) Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or Mini Strokes. U.S. National Institutes of Health.
20	ClinicalTrials.gov (NCT03224260) To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants. U.S. National Institutes of Health.
21	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033781)
22	ClinicalTrials.gov (NCT00541320) Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR). U.S. National Institutes of Health.
23	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1987).
24	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
25	ClinicalTrials.gov (NCT00074828) New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery. U.S. National Institutes of Health.
26	ClinicalTrials.gov (NCT05027074) A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis. U.S.National Institutes of Health.
27	ClinicalTrials.gov (NCT00808964) Study of NU172 as Anticoagulation in Patients Undergoing Off-pump CABG Surgery. U.S. National Institutes of Health.
28	The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits. Thromb Res. 2010 Oct;126(4):e339-43.
29	Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost. 1994 Nov;72(5):740-4.
30	Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost. 2014 Feb;111(2):279-89.
31	The effect of a prostaglandin DP-receptor partial agonist (192C86) on platelet aggregation and the cardiovascular system in healthy volunteers. Br J Clin Pharmacol. 1992 Oct;34(4):344-51.
32	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009728)
33	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1756).
34	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7727).
35	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041083)
36	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024917)
37	ClinicalTrials.gov (NCT02439190) CV004-007 Thrombosis Chamber Study. U.S. National Institutes of Health.
38	A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost. 2010 Jan;103(1):205-12.
39	Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis. J Thromb Haemost. 2010 Jun;8(6):1333-9.
40	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023539)
41	G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9.
42	ClinicalTrials.gov (NCT01954238) A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers. U.S. National Institutesof Health.
43	ClinicalTrials.gov (NCT04934891) A Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION547 Administered Subcutaneously to Healthy Subjects. U.S.National Institutes of Health.
44	Fondaparinux sodium. Drugs Today (Barc). 2002 Mar;38(3):185-94.
45	ClinicalTrials.gov (NCT01063595) A Trial to Investigate the Relative Efficacy, Safety, and Tolerability of Octaplas LG Versus Octaplas SD. U.S. National Institutes of Health.
46	ClinicalTrials.gov (NCT00367692) Study Evaluating PSI-697 in Patients With Scleritis. U.S. National Institutes of Health.
47	Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteers. J Clin Pharmacol. 2000 Nov;40(11):1245-56.
48	Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RW... J Med Chem. 2010 Feb 25;53(4):1843-56.
49	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005009)
50	The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost. 2011 Jun;9(6):1174-82.
51	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020651)
52	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8657).
53	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1979).
54	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000441)
55	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007792)
56	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010432)
57	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019932)
58	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1968).
59	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011626)
60	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2149).
61	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017772)
62	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018349)
63	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7682).
64	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002290)
65	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005994)
66	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021248)
67	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010575)
68	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020578)
69	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6072).
70	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003261)
71	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001868)
72	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024432)
73	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025952)
74	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000361)
75	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009197)
76	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027537)
77	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006051)
78	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012558)
79	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014574)
80	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003382)
81	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012496)
82	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022087)
83	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011969)
84	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014748)
85	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002792)
86	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1977).
87	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006092)
88	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007141)
89	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023381)
90	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003583)
91	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005011)
92	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021321)
93	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001874)
94	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010496)
95	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009534)
96	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022617)
97	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015808)
98	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005298)
99	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019722)
100	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7360).
101	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8059).
102	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007017)
103	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004683)
104	Inhibition of PAI-1: a new anti-thrombotic approach. Curr Drug Targets Cardiovasc Haematol Disord. 2002 Jun;2(1):27-42.
105	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004668)
106	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001867)
107	Imidazol-1-yl and pyridin-3-yl derivatives of 4-phenyl-1,4-dihydropyridines combining Ca2+ antagonism and thromboxane A2 synthase inhibition. J Med Chem. 1993 Oct 1;36(20):2964-72.
108	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010405)
109	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005534)
110	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6587).
111	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010798)
112	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003259)
113	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005051)
114	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012166)
115	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000372)
116	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009558)
117	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009151)
118	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004828)
119	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002814)
120	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009373)
121	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018421)
122	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010730)
123	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004708)
124	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003995)
125	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001755)
126	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005178)
127	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008792)
128	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005083)
129	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005037)
130	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006899)
131	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006901)
132	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1890).
133	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
134	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
135	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2360).
136	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1594).
137	Anti-thrombotic effect of ONO-8809, a novel TXA2/PG endoperoxide receptor antagonist. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:599-602.
138	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
139	Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM). J Clin Pharmacol. 2000 Oct;40(10):1129-40.
140	Himbacine derived thrombin receptor (PAR-1) antagonists: SAR of the pyridine ring. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4509-13.
141	Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis. J Thromb Thrombolysis. 2002 Oct;14(2):113-21.
142	Factor XI in haemostasis and thrombosis: past, present and future.Thromb Haemost. 2007 Jul;98(1):84-9.
143	Mutations in clotting factors and inflammatory bowel disease.Am J Gastroenterol. 2007 Feb;102(2):338-43. doi: 10.1111/j.1572-0241.2006.00974.x. Epub 2006 Dec 11.
144	Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor.Blood. 2015 Jan 22;125(4):710-9. doi: 10.1182/blood-2014-01-550285. Epub 2014 Oct 22.
145	Thrombosis risk modification in transgenic mice containing the human fibrinogen thrombin-binding gamma' chain sequence.J Thromb Haemost. 2009 Jan;7(1):102-10. doi: 10.1111/j.1538-7836.2008.03213.x. Epub 2008 Oct 30.
146	Platelet-collagen interaction: is GPVI the central receptor?.Blood. 2003 Jul 15;102(2):449-61. doi: 10.1182/blood-2002-12-3882. Epub 2003 Mar 20.
147	PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005 May;11(5):507-14.
148	Severe congenital protein C deficiency: description of a new mutation and prophylactic protein C therapy and in vivo pharmacokinetics.J Pediatr Hematol Oncol. 2008 Feb;30(2):166-71. doi: 10.1097/MPH.0b013e31815d8943.
149	Identification of a novel family of cell-surface proteins expressed in human vascular endothelium.J Biol Chem. 2002 Nov 29;277(48):46364-73. doi: 10.1074/jbc.M207410200. Epub 2002 Sep 21.
150	Vascular and thrombogenic effects of pulmonary exposure to Libby amphibole.J Toxicol Environ Health A. 2012;75(4):213-31. doi: 10.1080/15287394.2012.652055.
151	Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases.J Biol Chem. 2003 Aug 15;278(33):30725-31. doi: 10.1074/jbc.M301838200. Epub 2003 Jun 9.
152	The TUBB1 Q43P functional polymorphism reduces the risk of cardiovascular disease in men by modulating platelet function and structure.Blood. 2005 Oct 1;106(7):2356-62. doi: 10.1182/blood-2005-02-0723. Epub 2005 Jun 14.
153	VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites. Blood Adv. 2018 Mar 27;2(6):691-702.
154	A non-complement-fixing antibody to 2 glycoprotein I as a novel therapy for antiphospholipid syndrome.Blood. 2014 May 29;123(22):3478-87. doi: 10.1182/blood-2013-11-537704. Epub 2014 Mar 18.
155	Platelet FcgammaRIIA expression is associated with the alpha2 integrin C807T gene polymorphism in type 2 diabetes.Platelets. 2006 Mar;17(2):78-83. doi: 10.1080/09537100500260865.
156	Mechanisms and consequences of agonist-induced talin recruitment to platelet integrin alphaIIbbeta3.J Cell Biol. 2008 Jun 30;181(7):1211-22. doi: 10.1083/jcb.200803094. Epub 2008 Jun 23.
157	ACE2 activation promotes antithrombotic activity.Mol Med. 2010 May-Jun;16(5-6):210-5. doi: 10.2119/molmed.2009.00160. Epub 2010 Jan 22.
158	Degradation of circulating von Willebrand factor and its regulator ADAMTS13 implicates secreted Bacillus anthracis metalloproteases in anthrax consumptive coagulopathy.J Biol Chem. 2008 Apr 11;283(15):9531-42. doi: 10.1074/jbc.M705871200. Epub 2008 Feb 8.
159	Exacerbation of thrombotic events by diesel exhaust particle in mouse model of hypertension.Toxicology. 2011 Jul 11;285(1-2):39-45. doi: 10.1016/j.tox.2011.03.018. Epub 2011 Apr 8.
160	Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin.Blood. 2006 Jul 1;108(1):192-9. doi: 10.1182/blood-2006-01-0094. Epub 2006 Mar 2.
161	The role of C5a in the development of thrombotic glomerulonephritis in rats.Clin Exp Immunol. 2001 May;124(2):323-9. doi: 10.1046/j.1365-2249.2001.01513.x.
162	Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features.Leukemia. 2007 Jan;21(1):79-83. doi: 10.1038/sj.leu.2404377. Epub 2006 Aug 24.
163	Evaluating antithrombotic activity of HY023016 on rat hypercoagulable model.Eur J Pharmacol. 2016 Jun 15;781:190-7. doi: 10.1016/j.ejphar.2016.04.023. Epub 2016 Apr 13.
164	Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism.Blood. 2004 May 15;103(10):3773-6. doi: 10.1182/blood-2003-10-3422. Epub 2004 Jan 22.
165	Increased plasma C-reactive protein and interleukin-6 concentrations in patients with slow coronary flow.Clin Chim Acta. 2007 Oct;385(1-2):43-7. doi: 10.1016/j.cca.2007.05.024. Epub 2007 Jun 15.
166	Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.JAMA. 2010 Oct 27;304(16):1821-30. doi: 10.1001/jama.2010.1543.
167	Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ. 2006 Jun 6;174(12):1715-22. doi: 10.1503/cmaj.060664.
168	Systemic treatment with erythropoietin protects the neurovascular unit in a rat model of retinal neurodegeneration.PLoS One. 2014 Jul 11;9(7):e102013. doi: 10.1371/journal.pone.0102013. eCollection 2014.
169	Effect of sodium pentosan polysulphate on the thrombogenicity of prothrombin complex concentrates.Thromb Res. 1992 Jul 1;67(1):41-8. doi: 10.1016/0049-3848(92)90256-a.
170	Hematological and morphological investigation of thrombogenic mechanisms in the lungs of phenylhydrazine-treated rats.Exp Toxicol Pathol. 2013 May;65(4):457-62. doi: 10.1016/j.etp.2012.01.004. Epub 2012 Mar 7.
171	The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey.Clin Appl Thromb Hemost. 2007 Apr;13(2):166-71. doi: 10.1177/1076029606298990.
172	von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins.Blood. 2007 Mar 15;109(6):2424-9. doi: 10.1182/blood-2006-06-028241. Epub 2006 Nov 21.
173	Humanized mouse models of FcR clearance in immune platelet disorders.Blood Rev. 2002 Mar;16(1):3-5. doi: 10.1054/blre.2001.0170.
174	Role of the growth arrest-specific gene 6 (gas6) product in thrombus stabilization.Blood Cells Mol Dis. 2006 May-Jun;36(3):373-8. doi: 10.1016/j.bcmd.2005.12.038. Epub 2006 Mar 29.
175	Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.Thromb Haemost. 2007 Mar;97(3):435-43.
176	Roles of hepatocyte growth factor and mast cells in thrombosis and angiogenesis.Cardiovasc Drugs Ther. 2004 Jul;18(4):321-6. doi: 10.1023/B:CARD.0000041252.33870.74.
177	Heme-oxygenase induction inhibits arteriolar thrombosis in vivo: effect of the non-substrate inducer cobalt protoporphyrin.Eur J Pharmacol. 2009 Mar 15;606(1-3):109-14. doi: 10.1016/j.ejphar.2008.12.030. Epub 2009 Jan 10.
178	Mer receptor tyrosine kinase signaling participates in platelet function.Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):1118-23. doi: 10.1161/01.ATV.0000130662.30537.08. Epub 2004 May 6.
179	MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.Blood. 2008 Jul 1;112(1):141-9. doi: 10.1182/blood-2008-01-131664. Epub 2008 May 1.
180	ERK2 activation in arteriolar and venular murine thrombosis: platelet receptor GPIb vs. P2X.J Thromb Haemost. 2006 Feb;4(2):443-52. doi: 10.1111/j.1538-7836.2006.01745.x.
181	Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.Thromb Res. 2009 Nov;124(5):565-71. doi: 10.1016/j.thromres.2009.06.029. Epub 2009 Aug 18.
182	Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice.Cell Signal. 2007 Aug;19(8):1765-71. doi: 10.1016/j.cellsig.2007.03.012. Epub 2007 Apr 6.
183	Delayed-onset heparin-induced thrombocytopenia.Ann Emerg Med. 2005 Apr;45(4):417-9. doi: 10.1016/j.annemergmed.2004.08.005.
184	Thrombus versus wall biological activities in experimental aortic aneurysms.J Vasc Res. 2010;47(4):355-66. doi: 10.1159/000265569. Epub 2009 Dec 16.
185	Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors.J Exp Med. 2007 Feb 19;204(2):311-20. doi: 10.1084/jem.20061617. Epub 2007 Jan 22.
186	P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis.Arch Immunol Ther Exp (Warsz). 2006 Mar-Apr;54(2):75-84. doi: 10.1007/s00005-006-0010-6. Epub 2006 Mar 24.
187	Antithrombotic activity of kininogen is mediated by inhibitory effects of domain 3 during arterial injury in vivo.Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H2959-65. doi: 10.1152/ajpheart.00730.2006. Epub 2007 Feb 9.
188	The effect of ozagrel sodium on photochemical thrombosis in rat: therapeutic window and combined therapy with heparin sodium.Life Sci. 2002 Nov 8;71(25):2983-94. doi: 10.1016/s0024-3205(02)02165-3.
189	Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism.Thromb Haemost. 2005 Oct;94(4):787-90. doi: 10.1160/TH05-06-0412.
190	Soluble P-selectin and thrombomodulin-protein C-Protein S pathway in cyanotic congenital heart disease with secondary erythrocytosis.Thromb Res. 2003;112(4):223-7. doi: 10.1016/j.thromres.2003.12.011.
191	Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses. J Thromb Haemost. 2005 Apr;3(4):733-41. doi: 10.1111/j.1538-7836.2005.01186.x. Epub 2005 Feb 23.
192	Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension.Blood. 2011 Mar 31;117(13):3699-701. doi: 10.1182/blood-2010-12-327569.
193	Engineered human soluble calcium-activated nucleotidase inhibits coagulation in vitro and thrombosis in vivo.Thromb Res. 2008;122(4):541-8. doi: 10.1016/j.thromres.2007.12.002. Epub 2008 Jan 28.
194	Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels.Haematologica. 2005 Jun;90(6):851-3.
195	Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor.J Biol Chem. 2008 Dec 5;283(49):33846-53. doi: 10.1074/jbc.M805522200. Epub 2008 Sep 25.
196	LW protein: a promiscuous integrin receptor activated by adrenergic signaling.Transfus Clin Biol. 2006 Mar-Apr;13(1-2):44-9. doi: 10.1016/j.tracli.2006.02.022. Epub 2006 Mar 29.
197	Molecular basis for fibrinogen Dusart (A alpha 554 Arg-->Cys) and its association with abnormal fibrin polymerization and thrombophilia.J Clin Invest. 1993 Apr;91(4):1637-43. doi: 10.1172/JCI116371.
198	Dysfunctional nitric oxide signalling increases risk of myocardial infarction.Nature. 2013 Dec 19;504(7480):432-6. doi: 10.1038/nature12722. Epub 2013 Nov 10.
199	Diminished thrombogenic responses by deletion of the Podocalyxin Gene in mouse megakaryocytes.PLoS One. 2011;6(10):e26025. doi: 10.1371/journal.pone.0026025. Epub 2011 Oct 7.
200	Polymorphisms in the endothelial protein C receptor gene and thrombophilia.Thromb Haemost. 2007 Sep;98(3):564-9.
201	In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis.Kidney Int. 2005 Sep;68(3):1223-9. doi: 10.1111/j.1523-1755.2005.00515.x.